<DOC>
	<DOC>NCT01222702</DOC>
	<brief_summary>Subjects with Clostridium Difficile Infection (CDI) are randomized and then treated with study drug for 10 days. At the end of treatment, cure is assessed; subjects are then followed-up to assess any disease recurrence.</brief_summary>
	<brief_title>ACT-179811 in Patients With Clostridium Difficile Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>male or female at least 18 year old CDI 1st occurrence or 1st recurrence concurrent life threatening condition concomitant antimicrobial treatment for CDI concomitant treatment with another investigational drug.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>CDIFF</keyword>
	<keyword>CDI</keyword>
	<keyword>CDAD</keyword>
	<keyword>Clostridium difficile infection</keyword>
</DOC>